SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-QSB
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 1997
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ---- to ----
Commission File number 0-22146
APPLIED BIOMETRICS, INC.
(Exact name of small business issuer as specified in its charter)
Minnesota 41-1508112
(State of other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
501 E. Highway 13, Burnsville, MN 55337
(Address of principal executive office and zip code)
Issuer's telephone number, including area code (612) 890-1123
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for at least the past 90 days.
Yes _X_ No ___
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
At August 7, 1997, there were outstanding 4,169,587 shares of common
stock, $0.01 par value.
<PAGE>
APPLIED BIOMETRICS, INC.
Form 10-QSB Index
June 30, 1997
Page
----
Part I: Financial Information ......................................... 3
Item 1. Financial Statements .......................................... 3
Balance Sheets Unaudited at June 30, 1997 and
Audited at December 31, 1996 .................................. 3
Unaudited Statements of Operations for the
Three Month and Six Month Periods ended June 30, 1997
and 1996 ...................................................... 4
Audited Statements of Shareholders' Equity for the year ended
December 31, 1996 and for the unaudited Six Month Period ended
June 30, 1997 ................................................. 5
Unaudited Statements of Cash Flows for the
Six Month Periods Ended June 30, 1997 and
1996 .......................................................... 6
Notes to Unaudited Financial Statements ....................... 7
Item 2. Management's Discussion and Analysis or Plan
of Operation .................................................. 8
Part II: Other Information ............................................. 10
Item 1. Legal Proceedings ............................................. 10
Item 2. Changes in Securities ......................................... 10
Item 3. Defaults Upon Senior Securities ............................... 10
Item 4. Submission of Matters to a Vote of Security
Holders ....................................................... 10
Item 5. Other Information ............................................. 11
Item 6. Exhibits and Reports of Form 8-K .............................. 11
Signatures ............................................................... 11
<PAGE>
Part 1: Financial Information
Item 1. Financial Statements
APPLIED BIOMETRICS, INC.
Balance Sheets
<TABLE>
<CAPTION>
June 30,
1997 December 31,
(Unaudited) 1996
----------- -----------
<S> <C> <C>
ASSETS
Current Assets:
Cash and cash equivalents $ 520,307 $ 741,661
Short-term investments 4,903,825 5,632,791
Accounts Receivable 20,930 19,417
Inventory 216,243 222.476
Prepaid expenses and other current assets 135,455 226,665
----------- -----------
TOTAL CURRENT ASSETS 5,796,760 6,843,010
Property and equipment, net 550,526 528,398
Patents, net 104,717 109,307
Other assets 9,585 9,585
----------- -----------
TOTAL ASSETS $ 6,461,588 $ 7,490,300
=========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Trade accounts payable $ 146,941 $ 126,257
Accrued expenses and other liabilities 79,902 76,933
----------- -----------
TOTAL CURRENT LIABILITIES 226,843 203,190
SHAREHOLDERS' EQUITY
Common stock, $.01 par value, 10,000,000 shares
authorized: 4,169,587 and 4,168,987 shares
issued and outstanding at June 30, 1997
and December 31, 1996, respectfully 41,696 41,690
Additional paid-in capital 19,706,462 19,703,468
Accumulated deficit (13,513,413) (12,458,048)
----------- -----------
TOTAL SHAREHOLDERS' EQUITY 6,234,745 7,287,110
----------- -----------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 6,461,588 $ 7,490,300
=========== ===========
</TABLE>
<PAGE>
APPLIED BIOMETRICS, INC.
Statements of Operations
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
------------------ ----------------
June 30, June 30, June 30, June 30,
1997 1996 1997 1996
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Net sales $ 8,870 $ 26,350 $ 64,940 $ 43,725
Cost of sales 5,325 12,000 32,175 21,875
----------- ----------- ----------- -----------
GROSS PROFIT 3,545 14,350 32,765 21,850
----------- ----------- ----------- -----------
OPERATING EXPENSES:
Research and Development 390,825 167,172 710,273 329,740
Sales and Marketing 110,225 72,801 182,422 147,604
General and Administrative 196,260 158,236 359,853 283,545
----------- ----------- ----------- -----------
Total Operating Expenses 697,310 398,209 1,252,548 760,889
----------- ----------- ----------- -----------
OPERATING LOSS (693,765) (383,859) (1,219,783) (739,039)
Interest income 80,242 86,806 164,418 132,662
----------- ----------- ----------- -----------
NET LOSS ($ 613,523) ($ 297,053) ($1,055,365) ($ 606,377)
----------- ----------- ----------- -----------
LOSS PER COMMON SHARE ($ 0.15) ($ 0.07) ($ 0.25) ($ 0.17)
----------- ----------- ----------- -----------
Weighted average common shares
outstanding 4,169,587 4,017,096 4,169,537 3,662,782
----------- ----------- ----------- -----------
</TABLE>
<PAGE>
BIOMETRICS, INC.
STATEMENTS OF SHAREHOLDERS' EQUITY
<TABLE>
<CAPTION>
Additional
Common Stock Paid-in Accumulated
shares amount Capital Deficit
------------ ------------ ------------ ------------
<S> <C> <C> <C> <C>
December 31, 1995 2,943,410 $ 29,434 $ 13,507,155 $(11,089,087)
Private Placement net
of offering expenses of $587,133 860,000 8,600 4,564,267
Exercise of stock options warrants 365,577 3,656 1,632,046
Net loss (1,368,961)
------------ ------------ ------------ ------------
December 31, 1996 4,168,987 41,690 19,703,468 (12,458,048)
Exercise of stock options (unaudited) 600 6 2994
Net loss six months ended June 30, 1997 (unaudited) (1,055,365)
------------ ------------ ------------ ------------
Balance June 30, 1997 (unaudited) 4,169,587 $ 41,696 $ 19,706,462 $(13,513,413)
============ ============ ============ ============
</TABLE>
<PAGE>
APPLIED BIOMETRICS, INC.
Statements of Cash Flows
(Unaudited)
<TABLE>
<CAPTION>
Six Months Ended
--------------------------
June 30, June 30,
1997 1996
----------- -----------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(1,055,365) $ (606,377)
Adjustments to reconcile net loss to net
cash provided by operating activities:
Depreciation and amortization 82,812 44,197
Cash flows provided by (used for) changes in:
Accounts receivables (1,513) (26,350)
Inventory 6,233 (174,857)
Prepaid expenses and other assets 91,210 (28,155)
Accounts payable 20,684 4,163
Accrued expenses and other liabilities 2,969 (2,751)
----------- -----------
Net cash flows used by operating
activities (852,970) (790,130)
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Sales and maturities of short term investments 2,329,009 1,769,519
Purchases of short-term investments (1,600,043) (4,460,126)
Purchase of property and equipment (100,350) (107,797)
----------- -----------
Net cash used in investing activities 628,616 (2,798,404)
----------- -----------
CASH FLOW FROM FINANCING ACTIVITIES:
Net proceeds from private placement of
common stock -- 4,572,867
Proceeds from exercise of stock options
and warrants 3,000 1,635,702
----------- -----------
Net cash provided by financing activities 3,000 6,208,569
----------- -----------
Net (decrease) increase in cash and cash equivalents (221,354) 2,620,035
CASH AND CASH EQUIVALENTS:
Beginning of period 741,661 457,322
----------- -----------
End of period $ 520,307 $ 3,077,357
=========== ===========
</TABLE>
<PAGE>
BIOMETRICS, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
Note 1. Unaudited Interim Results
The accompanying unaudited financial statements have been prepared in
accordance with the instructions to Form 10-QSB and do not include all
the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of
management, all adjustments (consisting of normal recurring accruals)
considered necessary for a fair presentation have been included.
Operating results for the three and six months ended June 30, 1997 are
not necessarily indicative of the results that may be expected for the
year 1997.
These statements should be read in conjunction with the audited financial
statements and related notes for the year ended December 31, 1996
included in the Company's Form 10-KSB for the year ended December 31,
1996.
Note 2. Sale of Common Stock
In February of 1996 the Company sold 860,000 shares of common stock in a
private placement at $6.00 per share. Net proceeds to the Company, after
selling agent expenses and other offering expenses of $587,133, were
$4,572,867. In connection with this private placement, the Company issued
warrants to purchase 86,000 common shares. These warrants were
exercisable at $6.00 per share and expire in 2003.
<PAGE>
ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS
OR PLAN OF OPERATIONS
RESULTS OF OPERATIONS
For the three and six months ended June 30, 1997 and 1996.
NET SALES. For the three and six months ended June 30, 1997 the Company
had net sale of $8,870 and $64,940, respectively, compared to $26,350 and
$43,725 in the same periods in 1996. The decrease in net sales for the
three months ended June 30, 1997 is the result of no monitor sales in the
second quarter of 1997 compared to one monitor sale in the second quarter
of 1996 and a lower average selling price of the EVD Probe. The Company
believes that because of the early stage of its product roll-out that its
net sales will fluctuate on a quarter to quarter basis in future periods.
GROSS PROFIT. The Company's gross profit margin for the three and six
months ended June 30, 1997 was 40.0% and 50.5%, respectively, compared to
54.5% and 50.0% in the same periods in 1996. The decrease in the gross
profit margin for the three months ended June 30, 1997 is due to a lower
average selling price of the EVD Probe in 1997. The Company believes that
these margins are not necessarily representative of the margins it will
realize in the future.
RESEARCH AND DEVELOPMENT. For the three and six months ended June 30,
1997, Research and Development expense increased $223,653 and $380,533,
respectively, over the same periods in 1996. This increase is the result
of the continued development of the next generation Cardiac Output
Monitoring System that is expected to be completed late in the third
quarter of 1997. In future periods, the Company expects Research and
Development expenses to continue at approximately the same level or
increase slightly as the Company commences redevelopment of the TTD
device upon completion of the next generation Cardiac Output Monitoring
System.
SALES AND MARKETING. For the three and six months ended June 30, 1997,
Sales and Marketing expenses increased $37,424 and $34,818, respectively
over the same periods in 1996. This increase is the result of increased
sales personnel and other costs associated with the continued roll-out of
the Company's Cardiac Output Monitoring System.
GENERAL AND ADMINISTRATIVE. For the three and six months ended June 30,
1997, General and Administrative expenses increased $38,024 and $76,308,
respectively, over the same periods in 1996. This increase in expenses is
the result of increased personnel, legal expenses and other
administrative expenses associated with a higher level of activity.
<PAGE>
INTEREST INCOME. Interest Income decreased slightly for the three months
ended June 30, 1997 compared to the same period of 1996 because of fewer
funds available for investment. For the six months ended June 30, 1997,
Interest Income increased $31,756 as a result of more funds available for
investment. These additional funds came from a private placement of
common stock in February, 1996 and from the exercise of options and
warrants.
LIQUIDITY AND CAPITAL RESOURCES
Prior to 1993 the Company funded its operations through the sale of
private placement securities and notes from certain shareholders. In July
1993 the Company completed an initial public offering of common stock and
raised $5,137,648 in net proceeds.
In February 1996 the Company sold 860,000 shares of common stock at $6.00
per share in a private placement. Net proceeds to the Company was
$4,572,867.
Cash and short-term investments were $5,424,132 at June 30, 1997 and
working capital was $5,569,517. The Company used $852,970 of cash in its
operating activities including a net loss of $1,055,365.
The Company believes that its existing cash, cash equivalents and
short-term investments together with funds generated from operations will
enable the Company to meet its liquidity and capital needs for the next
twelve months.
Forward Looking Statements
Statements included in this Form 10-QSB that are not historical in nature
or current facts are "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Reform Act of 1995 and
are subject to certain risks and uncertainties that could cause actual
results to differ materially. Among these risks and uncertainties are (1)
the Company's limited revenues, history of losses and uncertainty of
future results; (2) the uncertainty of market acceptance of the Company's
product, which has recently been introduced, and (3) the fact the Company
has limited experience in manufacturing its product in commercial
quantities.
<PAGE>
PART II
OTHER INFORMATION
Item 1. Legal Proceedings
NONE
Item 2. Change in Securities
NONE
Item 3. Defaults Upon Senior Securities
NONE
Item 4. Submission of Matters to a Vote of Security Holders
On May 14, 1997, Applied Biometrics, Inc. held its annual shareholders
meeting. There were 4,169,587 shares of common stock eligible to vote.
(1) The votes cast for the five directors to serve until next
annual meeting or until their successors are elected and
qualify were:
FOR WITHHELD
--- --------
Joseph A. Marino 2,969,512 197,914
George E. Kline 2,999,112 168,314
William E. Engbers 2,999,512 167,914
Patrick Delaney 2,999,512 167,914
Demetre Nicoloff 3,155,579 11,847
(2) The votes cast to ratify and approve the appointment of Price
Waterhouse as independent public accountants for the Company
for the year ended December 31, 1997 were:
FOR 3,162,759 AGAINST 1,725 ABSTAIN 2,942
<PAGE>
Item 5. Other Information
NONE
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibit 27 - Financial Data Schedule
(b) No reports on Form 8-K were filed during the quarter ended
June 30, 1997.
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Applied Biometrics, Inc.
Registrant
/s/ Joseph A. Marino
Joseph A. Marino
President, CEO
/s/Gerald J. Prescott
Gerald J. Prescott,
Vice President and
Chief Financial Officer
Date: August 8, 1997
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> JUN-30-1997
<CASH> 529,307
<SECURITIES> 4,903,825
<RECEIVABLES> 20,930
<ALLOWANCES> 0
<INVENTORY> 216,243
<CURRENT-ASSETS> 5,796,760
<PP&E> 872,621
<DEPRECIATION> (322,095)
<TOTAL-ASSETS> 6,461,588
<CURRENT-LIABILITIES> 226,843
<BONDS> 0
0
0
<COMMON> 41,696
<OTHER-SE> 6,193,049
<TOTAL-LIABILITY-AND-EQUITY> 6,461,588
<SALES> 64,940
<TOTAL-REVENUES> 64,940
<CGS> 32,175
<TOTAL-COSTS> 32,175
<OTHER-EXPENSES> 710,273
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (1,055,365)
<INCOME-TAX> 0
<INCOME-CONTINUING> (1,055,365)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,055,365)
<EPS-PRIMARY> (.25)
<EPS-DILUTED> (.25)
</TABLE>
